Compare ATER & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATER | HIND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 74 | 18 |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 15.2M |
| IPO Year | 2019 | 2016 |
| Metric | ATER | HIND |
|---|---|---|
| Price | $1.27 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 146.5K | 18.4K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,975,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $1.75 |
| 52 Week High | $1.87 | $12.87 |
| Indicator | ATER | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 54.92 |
| Support Level | $0.59 | $1.99 |
| Resistance Level | $1.32 | $2.36 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.00 | 51.85 |
Aterian Inc is a consumer products company that operates through online retail channels, including Amazon, Walmart, Target, as well as its own direct-to-consumer websites. The company develops and manages a portfolio of owned brands, which are either internally incubated or acquired, offering products across multiple categories such as home and kitchen appliances, kitchenware, air quality appliances, health and beauty products, and essential oils. Its primary brands include Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, and Photo Paper Direct. The company generates revenue mainly through the online sale of its consumer products, with substantially all sales derived from the Amazon U.S. marketplace.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.